Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse

J. Radocha, L. Pour, T. Pika, V. Maisnar, I. Špička, E. Gregora, M. Krejčí, J. Minařík, K. Machálková, J. Straub, P. Pavlíček, R. Hájek, P. Žák,

. 2016 ; 96 (2) : 119-27. [pub] 20150421

Language English Country England, Great Britain

Document type Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc17001174

INTRODUCTION: The normalization of free light chain ratio (FLCr) has been introduced as a marker of stringent complete remission (CR) of multiple myeloma (MM). There is currently a lack of literature assessing the role of FLCr on MM disease progression and remission status. PATIENTS AND METHODS: A multicentered retrospective review of 125 patients with MM in CR and various FLCr values was completed. Parameters of interest included patient demographics, FLCr values, complete remission (CR)/relapse status, and time to progression (TTP). The FLCr values were recorded to provide time-dependent findings on the role of FLCr on progression-free survival and overall survival (OS). RESULTS: The mean follow-up time of 125 patients from five hospitals in the Czech Republic was 31 months. A total of 47.2% of patients relapsed (54 of 125) during the follow-up period. The median TTP of patients with normal FLCr (n = 66) was 54.4 and 40.2 months for patients with abnormal FLCr (n = 59) (P = 0.217). None of the patients reached median overall survival regardless of FLCr values (P = 0.821). In the subgroup of newly diagnosed patients after upfront autologous stem cell transplantation (ASCT), there were 55.6% of patients (35 of 63) with normal FLCr and 44.4% (28 of 64) with abnormal FLCr. A total of 34.9% of patients (22 of 63) relapsed in this subgroup. Within the abnormal FLCr patients, a median TTP was 56.3 months, but no median TTP was reached among the normal FLCr patients (P = 0.746). Median OS in patients with normal (nFLCr) and abnormal FLCr (aFLCr) was not reached (P = 0.787). CONCLUSION: We did not observe any benefit from FLCr normalization in CR in myeloma patients in terms of progression-free survival or overall survival.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17001174
003      
CZ-PrNML
005      
20170621105556.0
007      
ta
008      
170103s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/ejh.12556 $2 doi
024    7_
$a 10.1111/ejh.12556 $2 doi
035    __
$a (PubMed)25816709
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Radocha, Jakub $u 4th Department of Medicine - Hematology, Charles University Hospital and Faculty of Medicine Hradec, Králové, Czech Republic.
245    10
$a Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse / $c J. Radocha, L. Pour, T. Pika, V. Maisnar, I. Špička, E. Gregora, M. Krejčí, J. Minařík, K. Machálková, J. Straub, P. Pavlíček, R. Hájek, P. Žák,
520    9_
$a INTRODUCTION: The normalization of free light chain ratio (FLCr) has been introduced as a marker of stringent complete remission (CR) of multiple myeloma (MM). There is currently a lack of literature assessing the role of FLCr on MM disease progression and remission status. PATIENTS AND METHODS: A multicentered retrospective review of 125 patients with MM in CR and various FLCr values was completed. Parameters of interest included patient demographics, FLCr values, complete remission (CR)/relapse status, and time to progression (TTP). The FLCr values were recorded to provide time-dependent findings on the role of FLCr on progression-free survival and overall survival (OS). RESULTS: The mean follow-up time of 125 patients from five hospitals in the Czech Republic was 31 months. A total of 47.2% of patients relapsed (54 of 125) during the follow-up period. The median TTP of patients with normal FLCr (n = 66) was 54.4 and 40.2 months for patients with abnormal FLCr (n = 59) (P = 0.217). None of the patients reached median overall survival regardless of FLCr values (P = 0.821). In the subgroup of newly diagnosed patients after upfront autologous stem cell transplantation (ASCT), there were 55.6% of patients (35 of 63) with normal FLCr and 44.4% (28 of 64) with abnormal FLCr. A total of 34.9% of patients (22 of 63) relapsed in this subgroup. Within the abnormal FLCr patients, a median TTP was 56.3 months, but no median TTP was reached among the normal FLCr patients (P = 0.746). Median OS in patients with normal (nFLCr) and abnormal FLCr (aFLCr) was not reached (P = 0.787). CONCLUSION: We did not observe any benefit from FLCr normalization in CR in myeloma patients in terms of progression-free survival or overall survival.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protinádorové látky $7 D000970
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    12
$a transplantace hematopoetických kmenových buněk $7 D018380
650    _2
$a lidé $7 D006801
650    _2
$a lehké řetězce imunoglobulinů $x krev $7 D007147
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mnohočetný myelom $x krev $x diagnóza $x mortalita $x terapie $7 D009101
650    _2
$a staging nádorů $7 D009367
650    _2
$a prognóza $7 D011379
650    _2
$a recidiva $7 D012008
650    _2
$a indukce remise $7 D012074
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a analýza přežití $7 D016019
650    _2
$a autologní transplantace $7 D014182
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pour, Luděk $u Department of Internal Medicine-Hematooncology, University Hospital Brno, Brno, Czech Republic.
700    1_
$a Pika, Tomáš $u Department of Internal Medicine III, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic. $7 xx0071238
700    1_
$a Maisnar, Vladimír $u 4th Department of Medicine - Hematology, Charles University Hospital and Faculty of Medicine Hradec, Králové, Czech Republic.
700    1_
$a Špička, Ivan $u First Department of Medicine-Department of Hematology, 1st Faculty of Medicine and General University Hospital, Prague, Czech Republic.
700    1_
$a Gregora, Evžen $u Department of Clinical Hematology, University Hospital Kralovske Vinohrady, Prague, Czech Republic.
700    1_
$a Krejčí, Marta $u Department of Internal Medicine-Hematooncology, University Hospital Brno, Brno, Czech Republic.
700    1_
$a Minařík, Jiří $u Department of Internal Medicine III, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic. $7 xx0106330
700    1_
$a Machálková, Kateřina $u 4th Department of Medicine - Hematology, Charles University Hospital and Faculty of Medicine Hradec, Králové, Czech Republic.
700    1_
$a Straub, Jan $u First Department of Medicine-Department of Hematology, 1st Faculty of Medicine and General University Hospital, Prague, Czech Republic.
700    1_
$a Pavlíček, Petr $u Department of Clinical Hematology, University Hospital Kralovske Vinohrady, Prague, Czech Republic.
700    1_
$a Hájek, Roman $u Department of Clinical Hematology, University Hospital Ostrava, Ostrava, Czech Republic.
700    1_
$a Žák, Pavel $u 4th Department of Medicine - Hematology, Charles University Hospital and Faculty of Medicine Hradec, Králové, Czech Republic.
773    0_
$w MED00001620 $t European journal of haematology $x 1600-0609 $g Roč. 96, č. 2 (2016), s. 119-27
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25816709 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20170621110015 $b ABA008
999    __
$a ok $b bmc $g 1180314 $s 961741
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 96 $c 2 $d 119-27 $e 20150421 $i 1600-0609 $m European journal of haematology $n Eur J Haematol $x MED00001620
LZP    __
$a Pubmed-20170103

Find record

Citation metrics

Archiving options